다발성 골수종

104개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved104 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleSorrento Therapeutics, Inc.Phase 1

CAR2 Anti-CD38 A2 CAR-T Cells (CAR2 Anti-CD38 A2 CAR-T Cells)

Relapsed or Refractory Multiple Myeloma · CD38

#CD38#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

CART-138 cells (CART-138 cells)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleFundación Pública Andaluza para…Phase 2

CARTemis-1 (CARTemis-1)

Multiple Myeloma; Allogeneic Stem Cell Transplantation · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

CD19-BCMA CAR-T cells infusion (CD19-BCMA CAR-T cells infusion)

Refractory Lupus Nephritis; Systemic Sclerosis · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChang YingjunPhase 2

CD19-BCMA dual nanobody based CAR-T Cells (CD19-BCMA dual nanobody based CAR-T Cells)

Transplantation Candidates With Hematological Diseases · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleUnion Hospital, Tongji Medical …Phase 1

CD19/BCMA CAR-T cell therapy (CD19/BCMA CAR-T cell therapy)

Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T, CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells, CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing)

Refractory Idiopathic Membranous Nephropathy · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

CD19/BCMA-targeted CAR-T cells (CD19/BCMA-targeted CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Group Co.…Phase 1

CD19/CD20/BCMA CAR T cells (CD19/CD20/BCMA CAR T cells)

Non-Hodgkin Lymphoma, B-cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Group Co.…Phase 1

CD19/CD20/BCMA CAR-T (CD19/CD20/BCMA CAR-T)

Relapsed; Refractory · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Group Co.…Phase 1

BZE2204 (CD19/CD22/BCMA CAR-T cells, CD19/CD22/BCMA CAR-T cells(BZE2204))

Idiopathic Inflammatory Myopathies(IIM); Immune Thrombocytopenia(ITP) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Preclinical

CT0590 CAR T Cells (CT0590 CAR T Cells)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSichuan UniversityPhase 1

CXCR4 modified anti-BCMA CAR T cells (CXCR4 modified anti-BCMA CAR T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleO&D BioTech Group CO., LimitedPhase 1

Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D (Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D)

Relapsed or Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Dual Specificity CD38 and bcma CAR-T Cells (Dual Specificity CD38 and bcma CAR-T Cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Dual-targeting BCMA-CD19 CAR-T cell infusion (Dual-targeting BCMA-CD19 CAR-T cell infusion)

Relapsed or Refractory Multiple Myeloma (RRMM) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 1

EGFRt/BCMA-41BBz CAR T cell (EGFRt/BCMA-41BBz CAR T cell)

Multiple Myeloma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleFate TherapeuticsPhase 1

Allogenic CAR NK cells with BCMA expression (FT576, FT576 (Allogenic CAR NK cells with BCMA expression))

Multiple Myeloma; Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

1 x 10^8 cells per dose (FT836 CAR T cells, FT836 CAR T cells (1 x 10^8 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

4 / 6 pages

← PreviousNext →